Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Revenue (2016 - 2026)

Amphastar Pharmaceuticals has reported Revenue over the past 13 years, most recently at $183.1 million for Q4 2025.

  • For Q4 2025, Revenue fell 1.83% year-over-year to $183.1 million; the TTM value through Dec 2025 reached $719.9 million, down 1.65%, while the annual FY2025 figure was $719.9 million, 1.65% down from the prior year.
  • Revenue for Q4 2025 was $183.1 million at Amphastar Pharmaceuticals, down from $191.8 million in the prior quarter.
  • Over five years, Revenue peaked at $191.8 million in Q3 2025 and troughed at $101.7 million in Q2 2021.
  • A 5-year average of $151.7 million and a median of $158.1 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: soared 50.3% in 2023 and later decreased 4.38% in 2025.
  • Year by year, Revenue stood at $120.9 million in 2021, then increased by 11.69% to $135.0 million in 2022, then surged by 31.91% to $178.1 million in 2023, then grew by 4.73% to $186.5 million in 2024, then dropped by 1.83% to $183.1 million in 2025.
  • Business Quant data shows Revenue for AMPH at $183.1 million in Q4 2025, $191.8 million in Q3 2025, and $174.4 million in Q2 2025.